Healio interview
According to a study published in JAMA Network Open, 8.3% of US adults — equivalent to about 21.3 million people — reported ever having long COVID in 2024.
Long COVID can be tricky to diagnosis, and its treatment brings forth a host of other questions, particularly considering research’s limited findings so far.
There has been some progress. A study recently published in Annals of Internal Medicine found fluvoxamine to be potentially effective for improving quality of life and reducing fatigue in patients with long COVID.
“Although fatigue is a common symptom, it is not the only symptom,” the researchers wrote.
A randomized trial also published in Annals of Internal Medicine examined the efficacy of metformin and ursodeoxycholic acid for other long COVID symptoms. Both treatments failed to improve long COVID recovery, highlighting the challenges in treatment.
Healio spoke with Jonathan Shammash, MD, medical director of Hackensack Meridian Health’s COVID-19 Recovery Center, and Karla Oliveri, APN, a family nurse practitioner also with the COVID-19 Recovery Center, to learn more about how COVID-19 and long COVID treatment have evolved over the years, the most common symptoms they see, the important lessons they have learned in their work and more.
Read the full interview here.
Source : Healio
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.